We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
ANGLE
Revenue building and growth opportunities are developingScancell
Upcoming SCIB1 data could provide first proof of conceptHUTCHMED
Delivering on sharpened goals and prioritiesArecor Therapeutics
Pipeline and partnership progress plus upcoming catalystsFutura Medical
Haleon to commercialise MED3000 in the USFutura Medical
Key takeaways from Investor SeminarHUTCHMED
ASCO 2023: a growing body of evidence for fruquintinibFutura Medical
First months of Eroxon launch suggest a successful startFutura Medical
MED3000 FDA clearance marks a major step in the USAvacta
Diagnostics build-out continues with Coris acquisition